文章：

乳腺癌中的肿瘤突变负荷：当前证据、挑战与机遇

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities

原文发布日期：7 August 2023

DOI: 10.3390/cancers15153997

类型: Article

开放获取: 是

英文摘要：

Tumor mutational burden (TMB) correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. Based on data from the phase II KEYNOTE-158 study, the anti-PD-1 antibody pembrolizumab was granted approval for treating patients with advanced solid tumors and TMB ≥ 10 mutations per megabase. However, this trial did not include any patients with metastatic breast cancer; thus, several questions remain unanswered about the true role of TMB as a predictive biomarker of benefit to immune checkpoint inhibitor therapy in breast cancer. In this review, we will discuss the challenges and opportunities in establishing TMB as a predictive biomarker of benefit to immunotherapy in metastatic breast cancer.

摘要翻译： 

肿瘤突变负荷（TMB）与多种实体瘤类型的肿瘤新抗原负荷、T细胞浸润以及对免疫检查点抑制剂的反应相关。基于II期KEYNOTE-158研究的数据，抗PD-1抗体帕博利珠单获准用于治疗TMB≥10个突变/兆碱基的晚期实体瘤患者。然而，该试验未纳入任何转移性乳腺癌患者；因此，关于TMB作为乳腺癌免疫检查点抑制剂治疗获益预测性生物标志物的实际作用，仍有若干问题尚未明确。本综述将探讨在转移性乳腺癌中确立TMB作为免疫治疗获益预测性生物标志物所面临的挑战与机遇。

原文链接：

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities